ELISA-Validated Immunoreactive Polypeptides for Ehrlichia Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Human Monocytotropic Ehrlichiosis (HME) caused by Ehrlichia chaffeensis are inadequate due to the limited understanding of immunoreactive proteins, leading to undiagnosed cases and a lack of effective vaccines, with existing antigens representing an incomplete repertoire.
Innovation Solution
Identification and verification of highly immunoreactive E. chaffeensis proteins using ELISA tests, which can be used in diagnostic methods and vaccine compositions to detect infection and induce an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If low throughput approaches are used to define antigenic components, then some protective antigens can be identified, but the repertoire of immunoreactive proteins remains incomplete and limited
Solution Approach 1:
The patent changes the throughput parameter of the screening method from low throughput to high throughput by implementing automated ELISA assays that can simultaneously screen multiple hypothetical proteins. This allows comprehensive identification of immunoreactive proteins across the entire E. chaffeensis proteome rather than limiting analysis to a few selected antigens, thereby resolving the contradiction between identification accuracy and repertoire completeness.
Solution Approach 2:
The patent replaces manual, low-throughput experimental approaches with automated ELISA systems and bioinformatics prediction tools. This substitution enables systematic screening of all hypothetical proteins in the E. chaffeensis genome, transforming the limited antigen identification process into a comprehensive proteome-wide analysis that identifies complete immunoreactive protein repertoires.
2Ease of manufacture
If only a small group of known protective antigens is used, then vaccine development can proceed with available data, but diagnostic and vaccine effectiveness is limited due to incomplete antigen coverage
Solution Approach 1:
The patent develops a universal screening platform using ELISA assays and bioinformatics tools that can identify multiple immunoreactive proteins simultaneously. This multi-functional approach not only identifies protective antigens for vaccine development but also provides comprehensive diagnostic markers, thereby improving both vaccine effectiveness and diagnostic reliability while maintaining manufacturing feasibility through standardized protocols.
3Productivity
If genome-wide identification methods are implemented, then complete repertoire of immunoreactive proteins can be identified, but the complexity and resources required increase significantly
Solution Approach 1:
The patent segments the complex proteome-wide screening task into manageable components by first using bioinformatics tools to predict antigenic properties of individual hypothetical proteins, then prioritizing candidates for experimental validation. This segmentation reduces the complexity of the overall system by filtering proteins in silico before applying resource-intensive ELISA assays, thereby achieving complete protein identification with reduced operational complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The identified proteins provide a robust diagnostic tool and vaccine candidates, enabling accurate detection and potential treatment of HME, addressing the limitations of existing methods by providing a comprehensive repertoire of immunoreactive proteins.
Implementation Method 1
contacting an isolated polypeptide with the test sample, under conditions that allow peptide-antibody complexes to form; detecting the peptide-antibody complexes
Data Source
AI summary
Methods and compositions for diagnosing and vaccinating against Ehrlichia chaffeensis are provided.